The Lyme disease bacterium, Borrelia burgdorferi, has a documented ability to survive in tissue for extended periods in animal models, and without treatment its natural history in humans involves persistent infection lasting years, with latent periods and shifting symptoms across different organ systems. Whether that persistence continues after standard antibiotic treatment in humans is one of the most contested questions in infectious disease. The answer is not a clean yes or no. Instead, it depends on what you mean by “dormant” and which evidence you find most persuasive.
What Happens Without Treatment
Left untreated, Lyme disease is not a self-limiting illness that simply burns itself out. The spirochete can persist in the body for years, cycling through active disease phases and quiet intervals. Early infection often appears as a skin rash and flu-like symptoms, but the bacterium can eventually spread to joints, the heart, and the nervous system. These stages can be separated by weeks or months of apparent silence, which is what “dormant” looks like from the outside. The bacterium is still present; it is just not provoking obvious symptoms during those gaps. This pattern of latent periods interrupted by flare-ups is characteristic of several spirochetal infections, including syphilis and relapsing fever.
Relapsing fever Borrelia species, close relatives of the Lyme spirochete, have been shown to persist in the brain and reactivate disease after apparent clearance, reinforcing the idea that latency is a core survival strategy across the Borrelia genus.
How the Bacterium Hides
The Lyme spirochete is not a passive organism waiting to be found. It deploys several strategies to evade both the immune system and antibiotics, and understanding them helps explain why the dormancy question is so hard to resolve.
Shape-Shifting Under Stress
When conditions become hostile, whether from antibiotics, immune attack, or even exposure to human serum, B. burgdorferi can change its shape from the familiar corkscrew form into spherical structures called round bodies. These round bodies are viable; they can move, and they can revert to the active spiral form when conditions improve. This transformation happens in response to environmental stress and has been documented in multiple laboratory settings. Round bodies appear to provoke a different immune response than the spiral form, which could help the bacterium avoid detection.
Persister Cells
Like several other bacterial species, B. burgdorferi produces “persister” cells, a subpopulation that enters a metabolically dormant state and becomes tolerant to antibiotics without acquiring genetic resistance. The number of these persisters rises sharply as a bacterial culture ages and stops actively growing. Because standard antibiotics work best against bacteria that are actively dividing, persisters can survive treatment even when the drugs would kill their growing counterparts. This is not resistance in the traditional sense. The bacteria have not mutated. They have simply gone quiet, and antibiotics cannot reach a target that is not doing anything.
Biofilms
The spirochete can also form biofilms, communities of bacteria encased in a protective matrix. Biofilms are a well-known survival strategy across many bacterial species, and they are notoriously difficult for antibiotics to penetrate. Research has shown B. burgdorferi biofilms in infected mouse heart tissue, and some investigators have suggested that biofilm formation could contribute to ongoing symptoms in humans. Whether biofilms play a meaningful clinical role in post-treatment Lyme disease remains under investigation.
Antigenic Variation
Perhaps the most sophisticated trick in the spirochete’s arsenal is its ability to continually change the proteins on its surface so the immune system cannot lock onto a stable target. This is driven by a genetic system called vls, which reshuffles segments of a surface protein gene at high frequency during mammalian infection. The system can theoretically generate millions of distinct surface protein variants, making it nearly impossible for antibodies to keep up. Experiments have shown that this system is required for the bacterium’s long-term survival in infected mammals. One study demonstrated that the variable surface protein VlsE physically shields other surface molecules from antibody binding, so even if the immune system recognizes a deeper target, VlsE blocks antibodies from reaching it.
Hiding in Connective Tissue
The spirochete also exploits the body’s own structural scaffolding. B. burgdorferi gravitates toward the extracellular matrix, the mesh of proteins that surrounds cells in connective tissue. In chronically infected mice, the bacterium associates specifically with a molecule called decorin, clustering in decorin-rich pockets while being cleared from decorin-poor areas. These microenvironments may act as protective niches where the spirochete can avoid immune surveillance. Joints, skin, and connective tissue are all decorin-rich, which aligns with the sites where Lyme disease symptoms tend to concentrate.
What Animal Studies Show
The strongest evidence that B. burgdorferi can persist after antibiotic treatment comes from experiments in mice, dogs, and non-human primates. A systematic review of these animal studies found that while live, culturable bacteria were rarely recovered after treatment, spirochete DNA was frequently detected in tissues after antibiotics. In one well-known mouse study, animals treated with antibiotics were consistently culture-negative, meaning the bacteria could not be grown in the lab. But tissues from some treated mice remained positive by DNA testing, and intact spirochetes could be seen in collagen-rich tissues under a microscope. When ticks were allowed to feed on antibiotic-treated mice (a technique called xenodiagnosis), the ticks picked up spirochetes and transmitted them to new immunocompromised mice, which then tested DNA-positive. The authors concluded that following antibiotic treatment, mice remained infected with non-dividing but still infectious spirochetes, and that this was particularly the case when treatment began during the chronic stage of infection.
These results are striking, but translating mouse findings to humans comes with major caveats. Mice are not people. Their immune systems work differently, dosing regimens do not translate directly, and the strains used in labs may not behave identically to wild strains circulating in tick populations.
The Human Evidence Gap
In humans, the picture is far less clear. One xenodiagnosis study, the first of its kind in people, found B. burgdorferi DNA in ticks that fed on a patient with early Lyme disease during treatment and in ticks that fed on a patient with post-treatment symptoms. However, the researchers stated there was insufficient evidence to conclude that viable spirochetes were present in either case. DNA fragments can linger in tissue long after bacteria are dead, so detecting DNA alone does not prove ongoing infection.
Multiple randomized controlled trials have tested whether prolonged antibiotic treatment improves outcomes for patients with persistent symptoms after standard Lyme disease therapy. The results have been consistently negative. One European trial compared longer courses of doxycycline or a clarithromycin-hydroxychloroquine combination against placebo and found no significant difference in physical health scores among the three groups. An earlier pair of American trials similarly found no benefit from 90 days of intravenous and oral antibiotics compared to placebo. A major clinical review concluded that persistent active infection in humans has not been identified as a cause of the post-treatment syndrome, and that randomized trials have consistently failed to show benefit from extended antibiotics.
This does not mean patients are imagining their symptoms. It means whatever is driving those symptoms does not appear to respond to killing more bacteria with standard drugs, which in turn suggests that actively replicating bacteria may not be the primary problem.
What Drives Symptoms After Treatment
If the bacteria are mostly gone after standard treatment, why do some people remain sick? Several mechanisms have been proposed, and they are not mutually exclusive.
Leftover Bacterial Debris
One of the most compelling recent findings involves the cell wall material, or peptidoglycan, of the Lyme spirochete. Unlike most bacterial cell walls, B. burgdorferi peptidoglycan has unusual chemical properties that allow it to accumulate in tissues and resist degradation. Researchers have found this material in the joint fluid of patients with post-treatment Lyme arthritis, persisting even after antibiotics have eliminated the living bacteria. In mouse experiments, the peptidoglycan accumulated in the liver, where it was taken up by immune cells and liver cells, persisting for weeks. Although this liver accumulation caused minimal direct tissue damage, it triggered protein signatures resembling those seen in patients with chronic illness after acute infection. This debris is not alive, but it is immunologically active, essentially continuing to poke the immune system long after the living infection is gone.
Autoimmune Crossfire
Another proposed mechanism is molecular mimicry, where parts of the bacterium resemble the body’s own proteins closely enough to confuse the immune system. Research has identified structural similarities between B. burgdorferi surface proteins and human proteins like myosin. Antibodies produced against the bacterium can cross-react with these self-proteins, potentially driving inflammation in joints and the heart even after the infection clears. Additional work has identified candidate autoimmune targets in chronic Lyme arthritis, suggesting that immune-mediated damage can add to the effects of direct infection.
Central Sensitization
For patients whose primary complaints are pain, fatigue, and cognitive difficulty rather than joint swelling, a different mechanism may be at work. One hypothesis is that infection sensitizes the brain’s pain and fatigue signaling systems, and in some patients these heightened signals do not reset after the infection resolves. This “central sensitization” model would explain why symptoms can persist even when no trace of infection remains. The pattern resembles other post-infectious syndromes where an acute illness triggers lasting changes in how the nervous system processes signals.
Why Diagnosis Gets Complicated
The standard approach to Lyme disease diagnosis relies on detecting antibodies against the bacterium in a two-step blood test. This works reasonably well for confirming active infection in someone with a clear exposure history and compatible symptoms, but it has real limitations. At the early stage of disease, the two-tiered test is good at ruling in Lyme disease if positive, but has poor predictive value for ruling it out, which is why retesting after 30 days is recommended. For patients who were treated during the earliest stage, sensitivity can remain low even after a month.
Critically, antibody tests cannot distinguish between a past infection that has resolved and one that might still be active. A positive antibody result years after treatment tells you the immune system encountered the bacterium at some point, not that the bacterium is still there. This ambiguity feeds much of the controversy. Patients who feel unwell and test positive assume the infection is ongoing; clinicians see the positive result as a marker of prior exposure, not current disease. Both interpretations are plausible given the limitations of the test.
Researchers are working on new diagnostic approaches. One study identified a panel of six protein biomarkers that could distinguish patients with active Lyme disease from healthy individuals with high accuracy. If validated, tests based on such markers could eventually help distinguish active infection from post-infectious immune activity, a distinction the current tests cannot make.
Children and Long-Term Outcomes
Lyme disease is common in children, particularly in areas where infected ticks are prevalent. In one systematic assessment, about one in five parents reported that their child had at least one persistent symptom more than six months after treatment, and roughly half of those children experienced functional impairment, with lower physical health scores and greater fatigue. These numbers suggest that post-treatment symptoms are not solely an adult phenomenon.
However, the long-term cognitive outlook for children appears reassuring. A study comparing children with well-documented Lyme disease to their uninfected siblings found no differences on 17 of 18 neuropsychological measures, covering IQ, memory, processing speed, fine motor skills, and problem-solving. Parents’ subjective ratings of their children’s daily functioning also showed no group differences. The researchers concluded that children treated appropriately for Lyme disease have an excellent prognosis for normal cognitive functioning, a finding that contrasts with some of the more concerning reports in adult populations.
The Search for Drugs That Target Dormant Forms
If standard antibiotics struggle to kill persister cells and round bodies because those forms are metabolically inactive, then finding drugs that can reach dormant bacteria could change the treatment landscape. Several research groups have screened large libraries of existing FDA-approved drugs looking for compounds with activity against these resistant forms. One screen of over 1,500 approved drugs identified 165 that outperformed doxycycline and amoxicillin against stationary-phase B. burgdorferi persisters, with daptomycin, clofazimine, and certain cephalosporins showing the highest activity. A separate screen targeting specifically the round body form found that the antimalarial drug artemisinin had notable activity, along with daptomycin and several sulfa drugs.
These are laboratory findings, not clinical recommendations. A drug that kills persister cells in a test tube may not reach the right tissues at safe doses in a living person. But the research signals a shift in how scientists think about treating Lyme disease: rather than simply using longer courses of the same antibiotics, the goal is to find drugs that work against the specific bacterial forms that standard treatment misses. None of these candidates have been validated in human clinical trials for Lyme disease yet.
The “Chronic Lyme” Controversy
Few topics in medicine generate more friction between patients and mainstream infectious disease specialists than the question of chronic Lyme disease. Patients who remain symptomatic after treatment often feel dismissed by a medical system that tells them their infection is gone. Qualitative research has documented how people with persistent symptoms describe fundamental shifts in their daily lives, reduced social support, pervasive medical uncertainty, and an increased sense of personal responsibility for their own care. Many turn to alternative providers or unconventional therapies out of frustration with the conventional system’s inability to offer relief.
The mainstream position, reflected in guidelines from major medical societies, is that standard antibiotic courses are curative in the vast majority of cases, and that prolonged or repeated antibiotic therapy for persistent symptoms is unsupported by trial evidence and carries real risks including serious side effects and antibiotic resistance. Some clinicians outside the mainstream disagree, pointing to the animal persistence data and the limitations of current diagnostics as evidence that the standard position is too dismissive.
Adding to the complexity, some patients diagnosed with “chronic Lyme disease” may not have had Lyme disease in the first place. A systematic review examining the evidence for chronic tick-borne coinfections, which are frequently diagnosed by alternative practitioners, found unconvincing support for chronic symptomatic anaplasmosis, treatment-responsive chronic babesiosis in people with healthy immune systems, tick-borne Bartonella transmission, or simultaneous Lyme and Bartonella infection. The nonspecific nature of symptoms like fatigue, pain, and brain fog means other conditions can easily be misattributed to a dormant Lyme infection, especially when testing is ambiguous.
How Lyme Disease Compares to Other Spirochetal Infections
Lyme disease is not the only spirochetal infection known for latency and reactivation. Syphilis, caused by the related spirochete Treponema pallidum, famously progresses through active stages separated by years of clinical silence, then can re-emerge to attack the nervous system and cardiovascular system decades later. Both organisms share genetic systems with the potential for antigenic variation of surface molecules, and both establish chronic infections in untreated hosts. The syphilis spirochete is sometimes called a “stealth pathogen” because it keeps so few identifiable proteins on its outer surface that the immune system struggles to detect it. B. burgdorferi takes a different approach, displaying surface proteins but constantly changing them via its vls system, which can generate millions of variants. Relapsing fever Borrelia species, yet another branch of the family, use a similar strategy and have been shown to persist in the brain with the potential for disease reactivation. The capacity for prolonged persistence appears to be a shared family trait among spirochetes, not a unique feature of the Lyme pathogen.
What This Means If You Have Been Treated for Lyme Disease
If you completed a standard course of antibiotics for Lyme disease and still feel unwell months later, you are not alone, and you are not making it up. Estimates vary, but a meaningful minority of treated patients experience lingering symptoms. The most honest summary of the current science is that the bacterium clearly has the biological toolkit to persist in tissue, and animal experiments demonstrate that it can survive antibiotic treatment in at least some form. In humans, however, proof that living, active bacteria are driving post-treatment symptoms has remained elusive. The lingering symptoms may instead reflect leftover bacterial debris triggering ongoing immune activity, autoimmune processes set in motion during the original infection, or changes in how the nervous system processes pain and fatigue signals.
Practically, this means that seeking additional rounds of standard antibiotics is unlikely to help and could cause harm. It also means that research into anti-persister drugs, better diagnostics, and immune-modulating therapies holds the most promise for people stuck in the gray zone between a clear infection and a clean bill of health. The biology of the spirochete supports the plausibility of dormancy; the clinical evidence has not yet confirmed that dormancy is what drives ongoing human illness.